Biotech Values

[jq1234]

I'd agree extrapolating from the small number of very late stage of GPNMB+ TNBC to 2nd/3rd line vs an active comparator capecitabine increases the risk significantly. I was very comfortable with the small number in last line setting simply because comparator has almost no activity in this setting, and CDX011 is an active drug, thus chance of success is very high there. Now, CDX011 hasn't been tested in 2nd/3rd line setting, and it is going into ph3 in that setting. Hmmm...